How to Get Semaglutide: Prescription, Cost, Access

BMI divides your weight in kilograms by height in meters squared. A 5'10" person weighing 209 lbs hits a BMI of 30.0. A 5'4" person weighing 174 lbs also hits 30.0. The formula is simple, but it has blind spots.

Muscular individuals often register a BMI of 27-30 despite low body fat. A 2016 analysis of 40,420 adults found BMI misclassified 54 million Americans as "unhealthy" who had normal cardiometabolic markers (Tomiyama et al., *Int J Obes*, 2016). Your prescriber may use waist circumference (over 40 inches for men, over 35 inches for women) or body composition data alongside BMI to determine eligibility.

If your BMI falls between 27 and 30, document your weight-related conditions before the appointment. Bring lab results showing elevated A1C, fasting glucose, lipid panels, or a sleep study confirming apnea. Insurance companies often require this documentation for prior authorization.

The following diagnoses qualify as weight-related comorbidities for semaglutide eligibility:

• Type 2 diabetes (A1C 6.5% or above, or on glucose-lowering medication)
• Hypertension (blood pressure 130/80 or above, or on antihypertensives)
• Dyslipidemia (LDL above 130, triglycerides above 150, or on statins)
• Obstructive sleep apnea (documented by polysomnography or home sleep test)
• Cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• Non-alcoholic fatty liver disease (elevated ALT/AST with imaging evidence)

Medicare Part D now covers Wegovy for patients with BMI over 27 and established cardiovascular disease, following the SELECT trial results showing a 20% reduction in major adverse cardiovascular events (Lincoff et al., *NEJM*, 2023). This expanded access began in early 2026.

Step 1: Schedule the right appointment type. Request a "weight management consultation" or "metabolic health visit," not a general check-up. This signals medical necessity and ensures adequate time (20-30 minutes vs. 10).

Step 2: Bring documentation. Arrive with recent lab work (within 90 days): fasting glucose, A1C, lipid panel, liver enzymes. Bring your weight history if available. A documented pattern of weight gain over 2+ years strengthens prior authorization requests.

Step 3: Discuss medication options. Your doctor will evaluate whether Wegovy (weight loss indication) or Ozempic (diabetes indication) fits your clinical profile. If you have type 2 diabetes, Ozempic often gets faster insurance approval because it is the on-label use.

Step 4: Prior authorization submission. Your doctor's office submits clinical documentation to your insurance company. This typically includes BMI, comorbidities, prior weight-loss attempts (diet, exercise, other medications), and lab results. Response time: 3-14 business days.

Step 5: Pharmacy fulfillment. Once approved, the prescription routes to a specialty pharmacy (CVS Specialty, Accredo, or OptumRx are common). Specialty pharmacies ship temperature-controlled medication directly to your home. First shipment usually arrives within 5-7 business days.

For patients who need to reconstitute their own peptides, brand-name Wegovy and Ozempic come in pre-filled pens that require zero mixing. You dial the dose and inject.

Denials are common. A 2023 survey found 35% of initial prior authorizations for GLP-1 medications were denied (KFF Health Tracking Poll, 2023). Do not accept the first denial as final.

Appeal Step 1: Peer-to-peer review. Your doctor calls the insurance company's medical director to discuss your case. This overturns roughly 40-50% of initial denials.

Appeal Step 2: Written appeal. Submit a formal letter of medical necessity with supporting literature. Include the STEP 1 trial data showing 14.9% weight loss and the SELECT trial showing cardiovascular risk reduction. Attach all lab work and comorbidity documentation.

Appeal Step 3: External review. If the internal appeal fails, most states allow an independent external review by a physician not employed by the insurer. This is your strongest tool.

If all appeals fail, ask your prescriber about switching to Ozempic under the type 2 diabetes indication (if applicable) or explore the telehealth and cash-pay pathways below.

Step 1: Choose a platform. Legitimate telehealth providers employ board-certified physicians or nurse practitioners licensed in your state. They require a real medical evaluation, not just a questionnaire.

Step 2: Complete intake forms. You will enter your height, weight, medical history, current medications, and allergies. Most platforms require recent lab work or will order labs through a partner laboratory.

Step 3: Video or asynchronous consultation. A licensed prescriber reviews your information and determines eligibility. Some platforms use synchronous video calls (15-20 minutes). Others use asynchronous review where the provider evaluates your file and follows up via messaging.

Step 4: Prescription and shipping. If approved, the prescriber writes a prescription to either a retail pharmacy (if you have insurance) or a partner pharmacy. Medication ships in temperature-controlled packaging. Delivery: 2-5 business days.

Step 5: Ongoing monitoring. Reputable platforms require monthly check-ins to monitor weight, side effects, and dose titration. If you experience nausea or fatigue, your telehealth provider adjusts the protocol remotely.

Not all online semaglutide providers operate ethically. Watch for these warning signs:

• No medical evaluation required. Any platform that ships semaglutide without a provider consultation is operating illegally. A prescription requires a patient-provider relationship.
• No lab work requested. Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Providers who skip screening put you at risk.
• "Guaranteed approval" language. Legitimate providers deny patients who do not meet eligibility criteria. If everyone gets approved, the medical evaluation is a rubber stamp.
• No ongoing follow-up. Monthly monitoring during dose titration catches problems early. Platforms that prescribe and disappear are cutting corners.
• Unusually low prices for brand-name medication. If someone offers "Wegovy" at $99/month, it is not brand-name Wegovy. It may be compounded semaglutide marketed under a misleading name.

The prescription process mirrors injectable Wegovy: same BMI criteria, same prior authorization requirements, same insurance pathways. The difference is in dosing and administration.

Starting dose: 1.5 mg daily for 4 weeks, then escalating to 4 mg, 8 mg, 15 mg, and finally 25 mg. The titration schedule spans approximately 16 weeks.

How to take it: Swallow the tablet whole with no more than 4 oz (120 mL) of plain water on an empty stomach. Wait at least 30 minutes before eating, drinking, or taking other oral medications. The tablet uses a proprietary absorption enhancer (SNAC) that requires an empty stomach to work. Taking it with food reduces absorption by up to 40%.

Cost: Novo Nordisk launched oral Wegovy at $149/month for the 1.5 mg and 4 mg starting doses through an introductory offer (valid through August 2026). The 25 mg maintenance dose is $299/month cash price. With commercial insurance and a savings card, copays may drop to $25/month.

This format eliminates the need for injection supplies, refrigeration protocols, and reconstitution steps. For patients already comfortable with injections, the injectable dosage chart in mL remains the standard reference.

The FDA added semaglutide to the drug shortage list in March 2023 as demand outpaced Novo Nordisk's manufacturing capacity. During the shortage, compounding pharmacies were legally permitted to produce semaglutide under Section 503A (patient-specific prescriptions) and Section 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.

The FDA removed semaglutide from the shortage list on February 21, 2025. Following this: - 503A compounding pharmacies had until April 22, 2025 to stop compounding semaglutide injections - 503B outsourcing facilities had until May 22, 2025

As of March 2026, compounding pharmacies can only produce semaglutide in limited circumstances: patient-specific prescriptions where the prescriber documents that a commercially available product is not medically suitable for a specific patient (e.g., allergy to an inactive ingredient in brand-name formulations). Bulk compounding for general dispensing is no longer legal.

The FDA does not review compounded medications for safety, efficacy, or manufacturing quality. This creates measurable risks.

Danger scenario 1: Dosing inaccuracy. A 2024 FDA analysis of compounded semaglutide products found that some contained less than 50% of the labeled dose, while others contained significantly more. A patient expecting 0.25 mg who receives 0.5 mg will experience doubled side effects: severe nausea, vomiting, and potential dehydration. The side effects timeline assumes accurate dosing. Inaccurate compounding breaks that timeline.

Danger scenario 2: Contamination. The FDA issued warnings about compounded semaglutide products containing salt forms (semaglutide sodium and semaglutide acetate) that have never been studied in clinical trials. These altered molecular forms may produce different pharmacokinetics: faster absorption, unpredictable blood levels, or reduced efficacy. Novo Nordisk's brand products use the base peptide form tested in all STEP trials.

If you currently use compounded semaglutide, discuss transitioning to a brand-name product with your prescriber. The semaglutide dosage chart can help you map your current compounded dose to the equivalent brand-name pen dose. Some patients combine compounded semaglutide with B12; confirm with your provider whether your new brand-name protocol should include separate B12 supplementation.

Novo Nordisk savings cards reduce the copay to $0-$25/month for commercially insured patients. These cards are free to enroll and cover up to 24 fills. They do not work with Medicare, Medicaid, or other government insurance programs.

NovoCare Pharmacy offers direct-to-patient fulfillment with cash-pay pricing below retail. Wegovy injection at $499/month and Ozempic at $349-$499/month depending on dose.

GoodRx and similar discount programs negotiate lower cash prices at retail pharmacies. Pricing varies by pharmacy and ZIP code. Check multiple pharmacies before filling.

Commercial insurance: Coverage rates for semaglutide have improved since the SELECT cardiovascular trial results. Most large employer plans now cover Wegovy with prior authorization. Copays with manufacturer savings cards: $0-$25/month.

Medicare Part D: Now covers Wegovy for patients with BMI over 27 and established cardiovascular disease or high cardiovascular risk. This expansion, driven by the Inflation Reduction Act provisions and SELECT trial data, began rolling out in early 2026. Standard Part D cost-sharing applies.

Medicaid: Coverage varies dramatically by state. As of March 2026, approximately 20 states cover anti-obesity medications through Medicaid, but each has different prior authorization requirements, preferred drug lists, and step therapy mandates (requiring patients to fail cheaper medications first).

No insurance: The oral Wegovy introductory offer ($149-$299/month) is the most affordable brand-name option for uninsured patients. NovoCare Pharmacy direct pricing is the next best alternative.

If cost remains prohibitive, ask your prescriber about switching to tirzepatide, which may have different formulary placement on your specific insurance plan.

If using injectable Wegovy or Ozempic: 1. Remove the pen from the refrigerator 30 minutes before injection. Cold medication stings more. 2. Wash your hands. Clean the injection site (abdomen, thigh, or upper arm) with an alcohol swab. 3. Attach a new needle to the pen. Prime it according to the package insert (for first-time use only). 4. Dial to your starting dose: 0.25 mg for Ozempic, 0.25 mg for Wegovy. 5. Pinch a fold of skin. Insert the needle at a 90-degree angle. Press the dose button and hold for 6 seconds after the click. 6. Remove the needle. Do not rub the site. 7. Dispose of the needle in a sharps container. Cap the pen and return it to the refrigerator.

If using oral Wegovy: 1. Take the 1.5 mg tablet first thing in the morning on a completely empty stomach. 2. Swallow whole with no more than 4 oz of plain water. No coffee, no juice. 3. Wait 30 minutes before eating, drinking anything else, or taking other medications.

For a deeper look at unit-to-milligram conversions, see how many mg is 40 units of semaglutide.

Appetite suppression begins within 24-48 hours for most patients. You will notice reduced hunger at mealtimes and earlier satiety. This is the GLP-1 receptor agonism working on the hypothalamus. Do not force yourself to eat large meals. Shift to smaller, more frequent meals.

Nausea affects approximately 44% of patients during the first dose level (Wilding et al., *NEJM*, 2021). It typically peaks at 24-48 hours post-injection and resolves within 3-5 days. Bland foods, small portions, and adequate hydration reduce severity. If nausea is significant, read how to relieve nausea from semaglutide for a 9-strategy protocol.

Injection site reactions are mild in 95%+ of cases: slight redness, minor swelling, or a small bruise. Rotate injection sites weekly.

No immediate weight loss. The first week on 0.25 mg is a titration dose designed to acclimate your GI system. Meaningful weight loss typically begins at the 1.0 mg dose level or higher. Read how long does semaglutide take to work for realistic timelines by dose level.

What not to do: Do not increase the dose faster than the prescribed schedule. Do not skip meals entirely (this worsens nausea). Do not drink alcohol during the first week. Keep the pen refrigerated. Check does semaglutide need to be refrigerated for exact temperature ranges and travel protocols.